Skip to main content

Table 3 Cox univariable analysis for recurrence-free survival (RFS) according to patient, tumour and treatment modalities characteristicsa

From: Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China

  Univariable
Variable HR (95%CI) p
Age (years) (> 50 VS. ≤50) 0.96 (0.43–2.12) 0.918
Gender (Male VS. Female) 1.29 (0.48–3.43) 0.613
AJCC stage (III or IV VS. I or II) 46.17 (0.44–4836.63) 0.106
T stage (T3 or T4 VS. T1 or T2) 3.03 (1.10–8.37) 0.032
N stage (N1-N3 VS. N0) 0.86 (0.35–2.08) 0.730
Tumor size (> 20 mm VS. ≤20 mm) 0.97 (0.33–2.85) 0.960
History of smoking (Yes VS. No) 0.56 (0.13–2.37) 0.431
Chemotherapy (Yes VS. No) 0.62 (0.27–1.41) 0.250
Radiotherapy (Yes VS. No) 0.95 (0.41–2.21) 0.897
CRT (Yes VS. No) 0.75 (0.33–1.68) 0.481
  1. a: AJCC American Joint Committee on Cancer; HR Hazard ratio; CI Confidence interval; CRT Chemoradiotherapy